We are live on ! Find out more

DexCom

DXCM

Market cap $29.4B

77.94 USD

-0.38

0.49%

At close Updated Oct 23, 4:00 PM EDT

Pre-market

After hours

77.56

-0.38

0.49%

1 day

-0.49%

5 days

-9.49%

1 month

-11.16%

3 months

10.58%

6 months

24.31%

Year to date

17.13%

1 year

9.68%

5 years

-45.15%

10 years

277.8%

About: DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Employees: 11,100

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 55.8%

Neutral 41.9%

Negative 2.3%

7 healthcare stocks that stand out as investors pay up for the sector

Investors have pushed the healthcare sector to a record high, and some favored stocks have high projected revenue growth rates through 2028.

7 healthcare stocks that stand out as investors pay up for the sector

Zacks Investment Research

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence, especially for non-insulin Type 2 diabetes. The G7 15-Day sensor transition cut manufacturing costs, driving Q2 2026 gross margin up 400 bps to 64.1% and enabling 70% incremental operating margins. CONNECT study results published in NEJM reinforce DXCM's clinical leadership, particularly among GLP-1 users, supporting expanded coverage and future growth.

DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives

Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pill in ulcerative colitis, and a discovery about ovaries after menopause.

Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,.

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

Zacks Investment Research

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program's largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l.

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

Zacks Investment Research

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

See News Rankings

Price charts implemented using Lightweight Charts™